Oral N-acetyl-L-cysteine is a safe and effective precursor of cysteine

Relative bioavailability and toxicity of N-acetyl-l-Cys (NAC) were evaluated in 9-d chick growth assays. The bioavailability of NAC relative to Cys was determined by feeding young chicks a highly purified crystalline AA diet singly deficient in Cys. Bio-availability estimates were obtained using standard slope-ratio methodology. N-Acetyl-l-cysteine was shown to be as effective as Cys in supporting chick growth, and was assigned a relative bioavailability value of 100%. To assess toxicity, a nutritionally adequate corn-soybean meal diet was supplemented with graded concentrations of NAC (isomolar to 10, 20, 30, or 40 g/kg of Cys, as-fed). When NAC supplied 10 or 20 g/kg of Cys, chick growth performance was unaffected, but NAC supplying 30 or 40 g/kg of Cys reduced (P < 0.05) BW gain by 13 and 34%, respectively, relative to the unsupplemented control diet. Only plasma-free NAC was substantially increased (P < 0.05) because of excess dietary NAC; plasma-free Cys was unaltered. We concluded that dietary NAC is efficacious in supplying Cys in support of chick growth, and only large excesses of NAC are growth depressing. Hence, the human clinical benefits of oral NAC likely result from its ability to deliver Cys safely and effectively to the portal circulation.     

Zinc bioavailability in feed-grade sources of zinc

Chick bioassays were used to assess bioavailability of zinc (Zn) from inorganic Zn sources. A soy isolate-dextrose diet containing 13 mg Zn/kg diet was supplemented with feed-grade sources of ZnSO4.H2O (ZnSO4) or ZnO and fed for 2 wk after a 7-d Zn-depletion protest period. Bioavailability of Zn in ZnO relative to ZnSO4 (set at 100%) was determined by multiple regression slope-ratio methodology, using both growth and tibia Zn accumulation in chicks fed graded levels of ZnO and ZnSO4. Linear responses for gain and tibia Zn occurred at dietary Zn levels (ZnSO4.7H2O) between 13 mg/kg (basal) and 33 mg/kg (gain) or 53 mg/kg (total tibia Zn). Therefore, two bioavailability assays were conducted using supplemental Zn levels of 0, 7.5 and 15 mg/kg from each Zn source. When weight gain was regressed on supplemental Zn intake, bioavailability of Zn in ZnO was only 61.2% (P less than .01) that of ZnSO4. When total tibia Zn was regressed on supplemental Zn intake, bioavailability of Zn compared with ZnSO4 (set at 100.0%) was 44.1% (P less than .001) for ZnO. With chicks fed soy-based diets, bioavailability of Zn from ZnO was less than that of ZnSO4.     

ORIGINAL ARTICLE: Bioavailability of lysine for kittens in overheated casein is underestimated by the rat growth assay method*,†

Growth assays were performed to determine lysine bioavailability for kittens and rats in untreated and heated casein; these values were compared with estimates obtained with an in vitro method. Body weight, food intake, nitrogen and dry matter digestibility, and plasma lysine were determined during an 80‐day growth trial using kittens (n = 16). Body weight and food intake were determined during a 21‐day growth trial using weanling rats (n = 80). The growth data showed bioavailable lysine to be 102.4% and 100.2% (for untreated casein) and 66.1% and 51.7% (for heated casein) for kittens and rats, respectively. There was no relationship between plasma lysine and dietary lysine concentrations for kittens. There were no significant differences in nitrogen or dry matter digestibility among diets for kittens. The chemically reactive lysine content of untreated casein was 99.6%, and of heated casein was 67.1%. Heat treatment of casein resulted in significantly decreased lysine bioavailability as estimated by all methods. For untreated casein, both growth assays showed good agreement with the in vitro method for available lysine. For heated casein, the rat growth assay significantly underestimated bioavailable lysine as determined in kittens while the in vitro method closely approximated this value for the cat.     

Bioavailability of threonine in soybean meal for rats and chicks.

The bioavailability of threonine in soybean meal and the effects of the excess amino acids in soybean meal on the estimate were measured using rats and chicks in slope-ratio assays. In Exp. 1, a corn-based diet containing .23% threonine was supplemented with 0 to 45% L-threonine in .05% increments. The growth rate of weanling rats fed these diets increased quadratically (P less than .001) with L-threonine addition, the increase being essentially linear up to the .10% addition. In Exp. 2, the basal diet was supplemented with 0, .025, .050, .075, or 100% threonine from L-threonine, simulated soybean meal (a mixture of crystalline amino acids with a pattern designed to simulate soybean meal), or soybean meal. Regressions of partitioned weight gain and body N gain of rats vs supplemental threonine intake were calculated for each source using multiple regression. Slope ratios (soybean meal:L-threonine) were .91 for weight gain and .92 for body N gain. The additional amino acids in simulated soybean meal did not affect the estimate. For Exp. 3, a corn-soybean meal-based diet containing .48% threonine was supplemented with 0 to 60% L-threonine in .10% increments. The growth rate of broiler chicks fed the diets increased quadratically (P less than .001) with L-threonine addition. The increase was essentially linear up to the .10% addition. In Exp. 4, the basal diet was supplemented as in Exp. 2. Regressions of partitioned weight gain of chicks vs supplemental threonine intake were calculated for each source. The slope ratio for soybean meal:L-threonine was 1.03; however, the model exhibited fundamental invalidity and therefore the estimate should be interpreted with caution. The additional amino acids in the simulated soybean meal did not affect the value.     

Serological response in broiler chicks to different commercial Newcastle disease and infectious bronchitis vaccines.

Broiler chicks were administered vaccines against Newcastle disease and infectious bronchitis (both Arkansas and Massachusetts strains) at 2 weeks of age as either primary or secondary vaccinations. The vaccine was administered as a spray at 2 weeks of age to chicks that had received Newcastle disease vaccine alone, bronchitis vaccine alone, both vaccines in combination, or no vaccine at day 1 in the hatchery. The Newcastle disease hemagglutination-inhibition response was significantly lower in chicks receiving Newcastle disease vaccine as a secondary vaccine at 2 weeks than in those receiving the vaccine as a primary vaccination at that age. In contrast, the bronchitis hemagglutination-inhibition response was significantly higher in chicks receiving bronchitis vaccine as a secondary vaccination at 2 weeks than in those receiving the vaccine as a primary vaccination at that age.     

肉仔鸡对不同形态蛋白质吸收率的研究

为评价肉仔鸡对不同形态蛋白吸收差异性,将100只艾维茵雄肉仔鸡随机分为4个处理组,每个处理5个重复,每个重复5只鸡,进行氨基酸、酪蛋白和肽三种蛋白源的吸收率对比研究。结果表明:肉鸡对氨基酸组日粮总蛋白吸收率极显著高于肽组和酪蛋白组(P<0.01) ,总蛋白吸收率分别提高5.10 %和5.27 %;肽组和酪蛋白组日粮中多数氨基酸吸收率均显著(P<0.05)或极显著(P<0.01)低于氨基酸组的吸收率;相对而言,肽组和酪蛋白组中的天门冬氨酸、苏氨酸、丝氨酸、谷氨酸、甘氨酸、缬氨酸、脯氨酸、异亮氨酸和胱氨酸等吸收率同氨基酸组相比差异幅度较大。肽组日粮同酪蛋白组日粮总蛋白吸收率间无显著差异(P>0.05)。以上结果表明,游离氨基酸在肉仔鸡肠道中吸收率高于完整蛋白和肽,游离氨基酸具有吸收优势。     

鱤幼鱼对晶体氨基酸的利用效果及赖氨酸需求量的研究

本试验旨在探讨鱤幼鱼对晶体氨基酸的利用效果,并在此基础上确定鱤幼鱼赖氨酸的需求量.试验设计7组等氮饲料,其中对照组饲料蛋白质源全部为结合蛋白(鱼粉和酪蛋白),试验组饲料在对照组饲料的基础上利用晶体氨基酸替代部分酪蛋白,并通过添加不同水平的L-赖氨酸盐酸盐使赖氨酸水平在1.9％～4.5％之间(0.5％的梯度).试验选取初始体重为(2.36±0.08)g的鱤幼鱼378尾,随机分为7组(每组3个重复,每个重复18尾鱼),每组随机饲喂1种试验饲料.试验期为8周.结果表明:使用晶体氨基酸替代部分酪蛋白后,鱤幼鱼的生长性能虽有不同程度的下降,但3.46％和3.94％组的特定生长率与对照组无显著差异(P＜0.05),2.45％、2.95％、3.46％和3.94％组的饲料系数与对照组无显著差异(P＞0.05).各试验组的干物质、蛋白质和脂肪表观消化率均显著高于对照组(P＜0.05).鱤幼鱼的增重率,特定生长率,干物质和蛋白质表观消化率,肝胰脏脂肪酶活性,血清总蛋白、总胆固醇含量以及血清碱性磷酸酶活性均随饲料赖氨酸水平的升高而呈现先升高后降低的趋势.综上所述,鱤幼鱼可以利用饲料中的晶体氨基酸,利用效果与饲料氨基酸组成的平衡性有关;以增重率为指标,通过二次曲线模型得出鱤幼鱼赖氨酸需求量为饲料干重的3.40％(饲料粗蛋白质含量为饲料干重的46％).     

Gizzard ulceration in chicks fed cysteamine alone or in combination with a histamine H2-receptor antagonist

A study was carried out to evaluate the effect of cysteamine-HCl administration on gizzard ulceration and growth performance in broiler chicks. The effectiveness of the histamine H2-receptor antagonist, SKF 93479, in preventing gizzard ulcerations when given in combination with cysteamine-HCl was also examined. In the initial experiment cysteamine-HCl at the level of 2400 mg/kg of the diet caused severe gizzard ulceration and mortality and decreased feed intake and growth in chicks. The effect was not seen when cysteamine-HCl was administered at 600 or 1200 mg/kg of the diet. In Experiment 2 broiler chicks administered cysteamine-HCl at 1800 mg/kg of the diet had an increased incidence of gizzard ulceration and decreased growth performance. The severity of gizzard lesions and the depression of growth performance were not as great as in the group in Experiment 1 which received the 2400 mg/kg level of cysteamine-HCl. Addition of the H2 antagonist SKF 93479 at 54 mg/kg of the diet had no effect on improving gizzard ulcer score or growth performance in chicks which received cysteamine-HCl at the 1800 mg/kg of the diet level. From these data it appears that the administration of ulcerogenic levels of cysteamine-HCl in the chicken may involve a more complex pathogenesis in which factors other than acid hypersecretion are involved.     

Ronidazole pharmacokinetics after intravenous and oral immediate-release capsule administration in healthy cats

Ronidazole (RDZ) is an effective treatment for feline Tritrichomonas foetus infection, but has produced neurotoxicity in some cats. An understanding of the disposition of RDZ in cats is needed in order to make precise dosing recommendations. Single-dose pharmacokinetics of intravenous (IV) RDZ and immediate-release RDZ capsules were evaluated. A single dose of IV RDZ (mean 9.2mg/kg) and a 95mg immediate-release RDZ capsule (mean 28.2mg/kg) were administered to six healthy cats in a randomized crossover design. Plasma samples were collected for 48 h and assayed for RDZ using high pressure liquid chromatography (HPLC). Systemic absorption of oral RDZ was rapid and complete, with detection in the plasma of all cats by 10 min after dosing and a bioavailability of 99.64 (±16.54)%. The clearance of RDZ following IV administration was 0.82 (±0.07) ml/kg/min. The terminal half-life was 9.80 (±0.35) and 10.50 (±0.82) h after IV and oral administration, respectively, with drug detectable in all cats 48h after both administrations. The high oral bioavailability of RDZ and slow elimination may predispose cats to neurotoxicity with twice-daily administration. Less frequent administration should be considered for further study of effective treatment of T foetus-infected cats.     

Effects of glucose and amino acids on ghrelin secretion in sheep

Two experiments were conducted to elucidate the effects of post‐ruminal administration of starch and casein (Exp. 1), plasma amino acids concentrations (Exp. 2), and plasma glucose and insulin concentrations (Exp. 2) on plasma ghrelin concentrations in sheep. In Exp. 1, plasma ghrelin concentrations were determined by four infusion treatments (water, cornstarch, casein and cornstarch plus casein) in four wethers. Abomasal infusion of casein increased plasma α‐amino N (AAN) concentrations. Infusion of starch or casein alone did not affect plasma ghrelin concentrations, but starch plus casein infusion increased plasma levels of ghrelin, glucose and AAN. In Exp 2, we investigated the effects of saline or amino acids on ghrelin secretion in four wethers. Two hours after the initiation of saline or amino acid infusion into the jugular vein, glucose was also continuously infused to investigate the effects of blood glucose and insulin by hyper‐glycemic clump on plasma ghrelin concentrations. Infusion of amino acids alone raised plasma levels of ghrelin, but the higher plasma glucose and insulin concentrations had no effect on plasma ghrelin concentrations. These results suggest that high plasma levels of amino acids can stimulate ghrelin secretion, but glucose and insulin do not affect ghrelin secretion in sheep.     

A pharmacokinetic/clinical approach to postulate a local action of intra‐articular xylazine administration in the horse: a preliminary study

The study aims to evaluate whether the analgesic effect of intra‐articular (IA) route of xylazine administered to horses following arthroscopic surgery is due to a local or a systemic action. Two connected studies were performed. In the first, 1 mg/kg b.w. of xylazine was injected IA, and blood samples were taken to assess drug systemic absorption. In addition, systemic effects of the drug (sedation, ataxia or reduction of respiratory and cardiac rate) were registered. Control horses injected with saline IA were included in the study to exclude the influence of anaesthesia in the occurrence of these manifestations. In the second study, 1 mg/kg b.w. of xylazine was administered intravenously (i.v.) in healthy horses. Blood samples were collected to determine the concentrations of xylazine, and the same signs of systemic effects of the drug were recorded. By correlating these parameters, a systemic ‘no effect’ concentration was defined. Pharmacokinetic data after IA administration resulted in some xylazine absorption (bioavailability equal to 58.12%) with values above the systemic ‘no effect’ concentration. The occurrence of some signs related to systemic effects in horses receiving IA xylazine was significant compared with horses receiving saline. In conclusion, a systemic action of the drug after IA administration cannot be excluded.     

Pharmacokinetics of pentoxifylline in dogs after oral and intravenous administration

OBJECTIVE: To evaluate the pharmacokinetics of pentoxifylline (PTX) and its 5-hydroxyhexyl-metabolite, metabolite 1 (M1), in dogs after IV administration of a single dose and oral administration of multiple doses. ANIMALS: 7 sexually intact, female, mixed-breed dogs. PROCEDURE: A crossover study design was used so that each of the dogs received all treatments in random order. A drug-free period of 5 days was allowed between treatments. Treatments included IV administration of a single dose of PTX (15 mg/kg of body weight), oral administration of PTX with food at a dosage of 15 mg/kg (q 8 h) for 5 days, and oral administration of PTX without food at a dosage of 15 mg/kg (q 8 h) for 5 days. Blood samples were taken at 0.25, 0.5, 1, 1.5, 2, 2.5, and 3 hours after the first and last dose of PTX was administered PO, and at 5, 10, 20, 40, 80, and 160 minutes after PTX was administered IV. RESULTS: PTX was rapidly absorbed and eliminated after oral administration. Mean bioavailability after oral administration ranged from 15 to 32% among treatment groups and was not affected by the presence of food. Higher plasma PTX concentrations and apparent bioavailability were observed after oral administration of the first dose, compared with the last dose during the 5-day treatment regimens. CONCLUSIONS AND CLINICAL RELEVANCE: In dogs, oral administration of 15 mg of PTX/kg results in plasma concentrations similar to those produced by therapeutic doses in humans, and a three-times-a-day dosing regimen is the most appropriate.     

Amino acid-supplemented raw soybean diets for finishing swine

Growth and carcass traits of finishing swine fed amino acid-supplemented raw soybean (RSB) diets were examined. Experiments 1 and 2 were identical and included the following treatments: 1) corn-soybean meal (SBM), 2) corn-RSB (lysine equal to Diet 1), 3) Diet 2 + .15% L-lysine (LYS), 4) Diet 3 + .1% L-threonine (THR), 5) Diet 3 + .05% L-tryptophan (TRP), 6) Diet 3 + .15% DL-methionine (MET) and 7) Diet 3 + THR + TRP + MET equivalent to Diets 4 to 6. The unsupplemented corn-RSB diet reduced (P less than .05) gain, gain:feed, plasma urea N, loin eye area, and percentage of muscling compared with the corn-SBM diet. The addition of LYS or LYS + TRP generally improved these response variables, whereas the addition of LYS + THR or LYS + MET tended to reduce gain and gain:feed compared with the LYS addition alone. The LYS + THR + TRP + MET addition resulted in growth and carcass traits that were intermediate between those of pigs fed the corn-RSB and the corn-SBM diets but not different (P greater than .05) from either. Experiment 3 included Diets 1, 2 and 7 from Exp. 1 and 2, in addition to the following treatment: corn-RSB + LYS + THR + TRP. The LYS + THR + TRP addition improved (P less than .05) growth and carcass traits compared with the LYS + THR + TRP + MET addition.(ABSTRACT TRUNCATED AT 250 WORDS)     

Pharmacokinetics and tissue concentrations of firocoxib in sows following oral administration

The objectives of this study were to describe the pharmacokinetics of firocoxib following oral (PO) dosing and intravenous (IV) injection in sows. Seven healthy sows were administered 0.5 mg firocoxib/kg IV. Following a 23-d washout period, sows were administered firocoxib at 4.0 mg firocoxib/kg PO. Blood samples were collected at predetermined times for 72 hr after IV and 120 hr after PO administration. Plasma firocoxib concentration was measured using UPLC-MS/MS, and pharmacokinetic analysis was performed using noncompartmental procedures. Tissue firocoxib concentrations were determined at 5, 10 (n = 2/time point), and 21 d (n = 3) after PO administration. The geometric mean half-life following IV and PO administration was 16.6 and 22.5 hr, respectively. A mean peak plasma concentration (Cmax) of 0.06 µg/ml was recorded at 7.41 hr (T_max) after oral administration. Mean oral bioavailability was determined to be 70.3%. No signs of NSAID toxicity were observed on macroscopic and microscopic investigation. Firocoxib was detected in the skin with subcutaneous fat (0.02 µg/g) of one of three sows at 21 days postadministration. Additional work to establish appropriate meat withhold intervals in sows is required. Firocoxib was readily absorbed following PO administration. Further work is needed to better understand the analgesic effects for sows and piglets nursing sows administered firocoxib.     

The effect of protein status of the pig on the recovery and amino acid composition of endogenous protein in digesta collected from the distal ileum

Barrows with an average initial weight of 55 kg were fitted with simple T-cannulas at the distal ileum. The animals were fed a protein-free diet that consisted of 79.7% cornstarch, 10% sucrose, 3% Alphafloc (a source of cellulose), 3% canola oil and a vitamin-mineral premix. The pigs were fed 700 g of diet twice each day, at 0800 and 2000. A balanced amino acid mixture or a saline solution was administered intravenously while the protein-free diet was fed. Ileal digesta were collected for 24 h following a 7-d adaptation period. The administration of amino acids reduced (P less than .05) the recovery of endogenous protein from 18.5 to 12.7 g per kg dry matter intake. For the amino acids, the reduction was only significant (P less than .05) for proline, from 3.6 to .6 g per kg dry matter intake. If the total endogenous protein losses are assumed to be constant and the differences in the amino acid composition of non-reabsorbed endogenous protein, as observed in this study, are used to calculate true ileal digestibilities, differences in the digestibilities of the indispensable amino acids are large (up to 7.4 percentage units for threonine). The amino acid composition of endogenous protein determined in pigs fed a protein-free diet and parenterally administered with amino acids should provide a better estimate for the calculation of true amino acid digestibilities when based on the determination of true protein digestibility by the 15N-isotope dilution technique.     

玉米、豆粕中胆碱生物学效价的研究

用肉仔鸡进行为期1周(8～14日龄)的生长反应试验 ,用标准曲线及斜率比法测定了玉米、豆粕中胆碱生物学效价。按单因子试验设计 ,用艾维因商品代8日龄肉仔鸡160只 ,随机分为10个处理组 ,每组4个重复、每个重复4只鸡。通过在玉米淀粉酪蛋白纯合饲粮中分别添加胆碱(由氯化胆碱提供)0、300、600和900mg/kg,作出生长反应曲线。用玉米分别占42.21 %、72.24 %的两个玉米半纯合饲粮和豆粕比例分别为16.50 %、24.83 %的两个豆粕半纯合饲粮饲喂肉仔鸡 ,测出玉米和豆粕中胆碱生物学效价分别为57.47 %和45.97 %。用两个玉米 +豆粕混合日粮作加性效应检验 ,证明玉米、豆粕中胆碱生物学效价可加性良好     

The use of growth and liver aspartate aminotransferase to assess the effect of source of non-essential nitrogen on pyridoxine depletion, repletion and requirements of chicks.

1. Two experiments were carried out to study the relationship between growth, liver aspartate aminotransferase (Asp AT) and dietary pyridoxine to determine the pyridoxine requirement of chicks fed on diets containing crystalline essential amino acids with glutamic acid (GA) or diammonium citrate (DAHC) as the non-essential nitrogen source. 2. In one experiment purified diets containing isolated soy-protein with 0 or 3 mg pyridoxine/kg were used. The deficient chicks were significantly lighter, coverted food less efficiently and liver Asp AT activity was decreased. When deficient chicks were offered an adequate diet performance improved and Asp AT activity rapidly increased. 3. In the second experiment diets containing crystalline amino acids GA or DAHC combined with 0, 1 or 3 mg pyridoxine/kg (GA: 0, GA: 1, GA: 3, DAHC: 1, DAHC:3) were used. Growth rates of chicks fed on GA: 1 and GA: 3 were similar, whereas chicks fed on DAHC: 1 were significantly lighter than those given DAHC: 3. The growth data indicated a pyridoxine requirement for chicks fed on the GA diets of not more than 1mg/kg and of more than 1 mg/kg in those fed on diets containing DAHC. Asp AT activity varied significantly with dietary content of pyridoxine but not with the nitrogen source. When Asp AT activity was used to assess pyridoxine requirements, there was nof difference between chicks fed on GA or DAHC diets.     

Growth performance of weanling pigs fed corn-soybean meal diets with or without dried whey at various L-lysine.HCl levels

A total of 490 crossbred weanling pigs were used to evaluate the responses to and the subsequent interaction between dietary dried whey and crystalline L-lysine.HCl on postweanling growth and feed efficiency at two periods postweaning. The experiment was conducted as a 2 x 5 factorial arrangement of treatments in a randomized complete block design to evaluate two levels of edible-grade dried whey (0 or 25%) and five dietary lysine levels ranging from 1.10 to 1.50% in .10% increments using a corn-soybean meal mixture as the basal feedstuff. Pigs were allotted by weight, litter, and sex to seven replicates at weaning (23 +/- 2 d) and fed their treatment diets for a 35-d period. Daily gain and feed intake were greater (P less than .01) for both the 0- to 21- and the 22- to 35-d periods when dried whey was fed; the relative magnitude of the response to dried whey was greatest during the initial 21-d period. Growth responses during the 0- to 21-d period were, however, independent of dietary lysine level, suggesting that dietary lysine at a level of 1.10% is not the limiting nutrient in a corn-soybean meal diet or a corn-soybean meal diet with dried whey. From 22 to 35 d postweaning a linear growth response to lysine level occurred when the dried whey diet was fed, but no response was detected when lysine was added to the corn-soybean diet, resulting in a diet x lysine level interaction (P less than .10).(ABSTRACT TRUNCATED AT 250 WORDS)     

Methodology for assessing zinc bioavailability: efficacy estimates for zinc-methionine, zinc sulfate, and zinc oxide.

The bioavailability of zinc-methionine (ZnMET) was compared to that of feed-grade ZnSO4.H2O using three different diets: purified (crystalline amino acid [AA]), semipurified (soy isolate), and complex (corn-soybean [C-SBM]) diet. With the Zn-deficient purified or semipurified diet, weight gain and tibia Zn responded linearly to both ZnSO4.H2O and ZnMET supplementation. Common-intercept, multiple linear regression indicated differences in Zn bioavailability between ZnMET and ZnSO4.H2O for both diets as indicated by bone Zn. With the ZnSO4.H2O standard set at 100%, bioavailability of Zn from ZnMET was 117% (P less than .05) in the AA diet and 177% (P less than .01) in the soy isolate diet. The ZnMET was also compared to ZnSO4.H2O in a C-SBM diet containing 117 mg of Zn/kg. When high levels of Zn were added to this diet (0, 250, 500, and 750 mg/kg of supplemental Zn), consistent tissue Zn responses did not occur beyond the first increment. Addition of lower levels of supplemental Zn (0, 5, 10, 20, 30, 40 and 50 mg/kg) to a Zn-unsupplemented C-SBM basal diet (45 mg/kg of Zn), however, resulted in a broken-line, two-slope response in tibia Zn for both ZnMET and ZnSO4.H2O. Inflection points occurred at 60 and 54 mg of Zn/kg of diet for ZnSO4.H2O and ZnMET, respectively. The ratio of slopes (ZnMET:ZnSO4.H2O) below the inflection points was 206% (P less than .01), indicating that Zn was considerably more bioavailable in ZnMET than in ZnSO4.H2O for chicks consuming C-SBM diets. When feed-grade ZnO was compared to feed-grade ZnSO4.H2O in chicks consuming C-SBM diets, bone Zn slopes below the respective inflection points indicated that Zn was 61% bioavailable in ZnO relative to ZnSO4.H2O.     

Protection of neonatal broiler chicks against Salmonella Typhimurium septicemia by DNA containing CpG motifs

Oligodeoxynucleotides (ODN) containing cytosine-phosphodiester-guanine (CpG-ODN) motifs have been shown to stimulate the innate immune system against a variety of bacterial and protozoan infections in a variety of vertebrate species. The objective of this study was to investigate the immunostimulatory effect of CpG-ODN in neonatal broilers against Salmonella Typhimurium septicemia. Day-old broiler chicks, or embryonated eggs that had been incubated for 18 days, received 50 microg of CpG-ODN, 50 microg of non-CpG-ODN, or saline. Four days after exposure to CpG-ODN or day 2 posthatch, 1 x 10(6) or 1 x 10(7) colony-forming units (cfu) of a virulent isolate of Salmonella Typhimurium was inoculated by the subcutaneous route in the neck. Clinical signs, pathology, bacterial isolations from the air sacs, and mortality were observed for 10 days following challenge with Salmonella Typhimurium. The survival rate of birds in groups receiving either non-CpG-ODN or saline following Salmonella Typhimurium infection was 40%-45%. In contrast, birds receiving CpG-ODN had significantly higher survival rate of 80%-85% (P < 0.0001). Bacterial loads and pathology were low in groups treated with CpG-ODN compared to the groups receiving saline or non-CpG-ODN. Colony-forming units of Salmonella Typhimurium in the peripheral blood were significantly lower in birds treated with CpG-ODN compared to the group that received saline. This is the first time that CpG-ODN has been demonstrated to have an immunoprotective effect against an intracellular bacterial infection in neonatal broiler chickens following in ovo delivery.